Colorectal cancer statistics, 2017

By R. Siegel, K. Miller, S. Fedewa, D. Ahnen, R. Meester, A. Barzi, A. Jemal. Ca, 2017

3,739 citations recorded by the source corpus.

Colorectal cancer (CRC) is one of the most common malignancies in the United States. Every 3 years, the American Cancer Society provides an update of CRC incidence, survival, and mortality rates and trends. Incidence data through 2013 were provided by the Surveillance, Epidemiology, and End Results program, the National Program of Cancer Registries, and the North American Association of Central Cancer Registries. Mortality data through 2014 were provided by the National Center for Health Statistics. CRC incidence rates are highest in Alaska Natives and blacks and lowest in Asian/Pacific Islanders, and they are 30% to 40% higher in men than in women. Recent temporal patterns are generally similar by race and sex, but differ by age. Between 2000 and 2013, incidence rates in adults aged ≥50 years declined by 32%, with the drop largest for distal tumors in people aged ≥65 years (incidence rate ratio [IRR], 0.50; 95% confidence interval [95% CI], 0.48‐0.52) and smallest for rectal tumors in ages 50 to 64 years (male IRR, 0.91; 95% CI, 0.85‐0.96; female IRR, 1.00; 95% CI, 0.93‐1.08). Overall CRC incidence in individuals ages ≥50 years declined from 2009 to 2013 in every state except Arkansas, with the decrease exceeding 5% annually in 7 states; however, rectal tumor incidence in those ages 50 to 64 years was stable in most states. Among adults aged <50 years, CRC incidence rates increased by 22% from 2000 to 2013, driven solely by tumors in the distal colon (IRR, 1.24; 95% CI, 1.13‐1.35) and rectum (IRR, 1.22; 95% CI, 1.13‐1.31). Similar to incidence patterns, CRC death rates decreased by 34% among individuals aged ≥50 years during 2000 through 2014, but increased by 13% in those aged <50 years. Progress against CRC can be accelerated by increasing initiation of screening at age 50 years (average risk) or earlier (eg, family history of CRC/advanced adenomas) and eliminating disparities in high‐quality treatment. In addition, research is needed to elucidate causes for increasing CRC in young adults. CA Cancer J Clin 2017. © 2017 American Cancer Society. CA Cancer J Clin 2017;67:177–193. © 2017 American Cancer Society.

Subfields: Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/aab53a5643b44367b78b42f8a939cc2f0aff794f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pathology and Forensic Medicine

Citations in the corpus

ACG Clinical Guidelines: Colorectal Cancer Screening 2021. (2021, background): “Notably, CRC incidence among individuals age 50–64 years, which had historically declined by 2%–3% per year, has increased by 1% annually between 2011 and 2016 (1, 81).”
Early detection of cancer (2022, positive): “Early cancer detection research and development have produced tremendous health benefits, for example, through established screening approaches for cervical, breast, and colorectal cancers, which are now diagnosed less frequently at later stages than cancers without established screening (4) (Fig.”
Screening for Colorectal Cancer. (2021, methodology): “As in 2016, the USPSTF reviewed the evidence on (1) the effectiveness and comparative effectiveness of screening strategies to reduce colorectal cancer incidence, colorectal cancer mortality, or both; (2) the accuracy of various screening tests to detect colorectal cancer, advanced adenomas, or aden”
Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening (2018, background): “ethnic group, with incidence rates 20% higher and mortality rates 40% greater in blacks than in non-Hispanic whites.(48) The ACS updated its guideline for CRC screening in”
Classification of the Clinical Images for Benign and Malignant Cutaneous Tumors Using a Deep Learning Algorithm. (2018, background): “In 2017, it was estimated that 9,730 deaths were attributable to melanoma (Siegel et al., 2017).”
Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. (2021, background): “or adenomatous polyps based on size; and (3) the serious harms of”
Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society (2018, background): “A third stool test is the mt-sDNA test, which combines an immunochemical assay for hemoglobin, and assays for aberrantly methylated BMP3, NDRG, and NDRG4, mutated K-ras, and b-Actin in cells exfoliated from colonic neoplasms.103 Currently, there is only one mt-sDNA test marketed in the United States”
Colorectal Cancer and Nutrition (2019, background): “Due to effective screening measures, early interventions, better treatment options, mortality from colorectal cancer has decreased by about 35% from 1990 to 2007 and is currently down by about 50% from peak mortality rates [5].”
UNCERTAINTY MODELING AND INTERPRETABILITY IN CONVOLUTIONAL NEURAL NETWORKS FOR POLYP SEGMENTATION (2018, background): “Database Training Validation Test Resolution CVC-Colon [5] [1-76], [98-148], [221-273].”